Literature DB >> 11678950

Steroid hormone receptors in parotid gland cystadenolymphoma (Warthin's tumour).

A Teymoortash1, B M Lippert, J A Werner.   

Abstract

The aetiopathogenesis of cystadenolymphoma is mostly unknown. Cystadenolymphomas have a significantly higher incidence in the male than the female population. This might be as a result of endocrine dependency in this kind of tumour. The purpose of the present study was to determine the sex hormone receptor status in cystadenolymphoma. Tissue samples of cystadenolymphoma, pleomorphic adenoma and normal samples of the parotid gland were examined immunohistochemically for oestrogen and progesterone receptors. Progesterone-positive cells could be found in the salivary duct system of normal glands and in the epithelial components of cystadenolymphomas. There was no evidence for the presence of oestrogen receptor in any sample studied. The evidence of progesterone receptors in cystadenolymphoma may implicate a potential role of endocrine factors in the development of this tumour.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678950     DOI: 10.1046/j.1365-2273.2001.00494.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  3 in total

Review 1.  Tissue that has lost its track: Warthin's tumour.

Authors:  A Teymoortash; J A Werner
Journal:  Virchows Arch       Date:  2005-05-24       Impact factor: 4.064

Review 2.  A perspective of comparative salivary and breast pathology. Part I: microstructural aspects, adaptations and cellular events.

Authors:  Asterios Triantafyllou; Jennifer L Hunt; Kenneth O Devaney; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-07       Impact factor: 2.503

3.  Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma.

Authors:  Ana Amélia de Souza; Albina Altemani; Ney Soares de Araujo; Lucas Novaes Texeira; Vera Cavalcanti de Araújo; Andresa Borges Soares
Journal:  Clin Pathol       Date:  2019-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.